Unknown

Dataset Information

0

The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster.


ABSTRACT:

Objectives

We hypothesized that systemic administration of high-mobility group box 1 fragment attenuates the progression of myocardial fibrosis and cardiac dysfunction in a hamster model of dilated cardiomyopathy by recruiting bone marrow mesenchymal stem cells thus causing enhancement of a self-regeneration system.

Methods

Twenty-week-old J2N-k hamsters, which are ?-sarcoglycan-deficient, were treated with systemic injection of high-mobility group box 1 fragment (HMGB1, n = 15) or phosphate buffered saline (control, n = 11). Echocardiography for left ventricular function, cardiac histology, and molecular biology were analyzed. The life-prolonging effect was assessed separately using the HMGB1 and control groups, in addition to a monthly HMGB1 group which received monthly systemic injections of high-mobility group box 1 fragment, 3 times (HMGB1, n = 11, control, n = 9, monthly HMGB1, n = 9).

Results

The HMGB1 group showed improved left ventricular ejection fraction, reduced myocardial fibrosis, and increased capillary density. The number of platelet-derived growth factor receptor-alpha and CD106 positive mesenchymal stem cells detected in the myocardium was significantly increased, and intra-myocardial expression of tumor necrosis factor ? stimulating gene 6, hepatic growth factor, and vascular endothelial growth factor were significantly upregulated after high-mobility group box 1 fragment administration. Improved survival was observed in the monthly HMGB1 group compared with the control group.

Conclusions

Systemic high-mobility group box 1 fragment administration attenuates the progression of left ventricular remodeling in a hamster model of dilated cardiomyopathy by enhanced homing of bone marrow mesenchymal stem cells into damaged myocardium, suggesting that high-mobility group box 1 fragment could be a new treatment for dilated cardiomyopathy.

SUBMITTER: Kido T 

PROVIDER: S-EPMC6281303 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7147742 | BioStudies
2020-01-01 | S-EPMC7248204 | BioStudies
2016-01-01 | S-EPMC4720305 | BioStudies
2015-01-01 | S-EPMC4498601 | BioStudies
2020-01-01 | S-EPMC7028717 | BioStudies
2018-01-01 | S-EPMC6816880 | BioStudies
2019-01-01 | S-EPMC6617791 | BioStudies
2015-01-01 | S-EPMC4270955 | BioStudies
1000-01-01 | S-EPMC314179 | BioStudies
2013-01-01 | S-EPMC3746388 | BioStudies